Role of tumor necrosis factor (TNF) and interleukin-6 (IL-6) in the pathogenesis of late complications of menopause. Effects of hormone replacement therapy on TNF and IL-6 expression;Rola czynnika martwicy nowotworu i interleukiny w patogenezie późnych nastȩpstw menopauzy. Wpływ hormonalnej terapii zastȩpczej na ich ekspresjȩ

Polski Merkuriusz Lekarski

Volumn 18, Issue 108, 2005, Pages 724-727

  Rachón, Dominik ^a  

^a AM w Gdańsku ^*  (Poland)

Author keywords

Alzheimer's disease; Atherosclerosis; Coronary heart disease; Cytokines; Estrogens; Hormone replacement therapy; IL 6; Inflammation; Menopause; Osteoporosis; TNF; Women

Indexed keywords

ESTROGEN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HORMONE SUBSTITUTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; MENOPAUSE; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE; REVIEW;

DOWN-REGULATION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INTERLEUKIN-6; MENOPAUSE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21744440248     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Abraham C.R. i wsp.: Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell, 1988, 52, 487-501.
2. Aggarwal B.B. i wsp.: Tumor necrosis factors: developments during the last decade. Eur. Cytokine Netw., 1996, 7, 93-124.
3. Akira S. i wsp.: IL-6 and NF-IL-6 in acute-phase response and viral infection. Immunol. Rev., 1992, 127, 25-50.
4. Akoum A. i wsp.: Secretion of interleukin-6 by human endometriotic cells and regulation by proinflammatory cytokines and sex steroids. Hum. Reprod., 1996, 11, 2269-75.
5. Basak S. i wsp.: Expression of pro-inflammatory cytokines in mouse blastocysts during implantation: modulation by steroid hormones. Am. J. Reprod. Immunol., 2002, 47, 2-11.
6. Belmin J. i wsp.: Increased production of tumor necrosis factor and interleukin-6 by arterial wall of aged rats. Am. J. Physiol. 199, 268, H2288-93.
7. Berg G. i wsp.: Cytokine changes in postmenopausal women treated with estrogens: a placebo-controlled study. Am. J. Reprod. Immunol., 2002, 48, 63-9.
8. Bernard-Poenaru O. i wsp.: Bone-resorbing cytokines from peripheral blood mononuclear cells after hormone replacement therapy: a longitudinal study. Osteoporos Int., 2001, 12, 769-76.
9. Beutler B. i wsp.: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 1985, 229, 869-71.
10. Bjornberg F. i wsp.: Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms. Lymphokine Cytokine Res., 1994, 13, 203-11.
11. Brookmeyer R. i wsp.: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public. Heath., 1998, 88, 1337-42.
12. Cantatore F.P. i wsp.: Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin. Rheumatol. 1995, 14, 157-60.
13. Deswal A. i wsp.: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation, 200, 103, 2055-9.
14. Eaker E.D. i wsp.: Cardiovascular disease in women. Circulation, 1993, 88, 1999-2009.
15. Elhage R. i wsp.: Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation, 1998, 97, 242-4.
16. Ganter U. i wsp.: Alpha 2-macroglobulin synthesis in interleukin-6- stimulated human neuronal (SH-SY5Y neuroblastoma) cells. Potential significance for the processing of Alzheimer beta-amyloid precursor protein. FEBS Lett 1991, 282, 127-31.
17. Girasole G. i wsp.: Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro. Clin. Endocrinol., 1999, 51, 801-7.
18. Gornstein R.A. i wsp.: Androgens modulate interleukin-6 production by gingivial fibroblasts in vitro. J. Periodontol., 1999, 70, 604-9.
19. Grossman R.M. i wsp.: Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci., USA, 1989, 86, 6367-71.
20. Hakovirta H. i wsp.: Function of interleukin-6 as an inhibitor of meiotic DNA synthesis in the rat seminiferous epithelium. Mol. Cell. Endocrinol., 1995, 108, 193-8.
21. Hama T. i wsp.: Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci. Lett., 1989, 104: 340-4.
22. Heyser C.J. i wsp.: Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc. Natl. Acad. Sci., USA, 1997, 94, 1500-5.
23. Holm P.: Effect of estrogen on development of atherosclerosis. A review of experimental animal studies. Dan. Med. Bull., 2001, 48, 146-60.
24. Horowitz M.C.: Cytokines and estrogen in bone: anti-osteoporotic effects. Science, 1993, 260, 626-7.
25. Hotamisligil G.S. i wsp.: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993, 259, 87-91.
26. Hull M. i wsp.: The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behav. Brain. Res. 1996, 78, 37-41.
27. Ikeda U. i wsp.: Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am. J. Physiol., 1991, 260, H1713-7.
28. Ikeda U. i wsp.: Interleukin 6 gene transcripts are expressed in atherosclerotic lesions of genetically hyperlipidemic rabbits. Atherosclerosis, 1992, 92, 213-8.
29. Kania D.M. i wsp.: Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J. Am. Geriatr. Soc., 1995, 43, 236-9.
30. Krishnaswamy G. i wsp.: Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J. Interferon Cytokine Res. 1999, 19, 91-104.
31. Kurihara N. i wsp.: IL-6 stimulates osteoclast-like multinucleated cell formation in long-term human marrow cultures by inducing IL-1 release. J. Immunol. 1990, 144, 4226-30.
32. Libby P. i wsp.: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J. Cardiovasc. Pharmacol., 1995, 25 (suppl 2), 9-S12.
33. Lindsay R. i wsp.: The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gyriecol., 1984, 63, 759-63.
34. Lotz M. i wsp.: B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J. Exp. Med., 1988, 167, 1253-8.
35. Mackiewicz A. i wsp.: Interleukin-6-type cytokines and their receptors for gene therapy of melanoma. Ann. N. Y. Acad. Sci., 1995, 762, 361-73.
36. Manolagas S.C. i wsp.: Bone marrow, cytokines, and bone remodelling. Emerging insights into the pathophysiology of osteoporosis. New. Engl. J. Med., 1995, 332, 305-311.
37. Margaglione M. i wsp.: Genetic modulation of plasma fibrinogen concentrations: possible importance of interleukin-6. J. Thromb. Thrombolysis, 1996, 3, 51-6.
38. Mayer P. i wsp.: Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Exp. Hematol., 1991, 19, 688-96.
39. Mohamed-Ali V. i wsp.: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab., 1997, 82, 4196-200.
40. Montes M.J. i wsp.: Constitutive secretion of interleukin-6 by human decidual stromal cells in culture. Regulatory effect of progesterone. Am. J. Reprod. Immunol., 1995, 34, 188-94.
41. Mrak R.E. i wsp.: Glial cytokines in Alzheimer's disease. Hum. Pathol., 1995, 26, 816-23.
42. Muraguchi A. i wsp.: The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med., 1988, 167, 332-44.
43. Navarro S. i wsp.: Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication. Blond, 1991, 77, 461-71.
44. Olsen N.J. iwsp.: Gonadal steroids and immunity. Endor. Rev., 1996, 17, 369-84.
45. Pacifici R. i wsp.: Effect of surgical menopause and estrogen replacement on cytokine release form human blood mononuclear cells. Proc. Natl. Acad. Sci., USA. 1991, 88, 5134-8.
46. Pioli G. i wsp.: Spontaneous release of interleukin-1 and interleukin-6 by peripheral blood mononuclear cells after oophorectomy. Clin. Sci., 1992, 83, 503-7.
47. Puder J.J. i wsp.: Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women. J. Clin. Endocrinol. Metab., 2001, 86, 2403-08.
48. Rachoń D. i wsp.: Serum interleukin-6 levels and BMD at the femoral neck in postmenopausal women with type 1 diabetes. Diabetic Med., 2003, 20, 475-480.
49. Rachoń D. i wsp.: Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J. Endocrinol. 2002, 172 (2), 387-395.
50. Rachoń D.: The antiinflammatory properties of medroxyprogesterone acetate. Circulation, 2002, 106, e185.
51. Rachoń D.: Ocena ekspresji czynnika martwicy nowotworu (TNF) oraz interleukiny-6 (IL-6) przed i w trakcie stosowania hormonalnej terapii zastȩpczej (HTZ) u kobiet w wieku pomenopauzalnym. Rozprawa doktorska, Akademia Medyczna w Gdańsku, Gdańsk 2003.
52. Ralston S.H. i wsp.: Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J. Bone Miner. Res., 1990, 5, 983-8.
53. Riggs B.L. i wsp.: A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res., 1998, 13, 763-73.
54. Rogers A. i wsp.: Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood. J. Bone Miner. Res., 1998, 13, 1577-86.
55. Ross R.: Atherosclerosis - an inflammatory disease. N. Engel J. Med., 1999, 340, 115-26.
56. Saucedo R. i wsp.: Transdermal estradiol in menopausal women depresses interleukin-6 without affecting other markers of immune response. Gynecol, Obstem, Incest, 2002, 53, 114-7.
57. Solerte S.B. i wsp.: Menopause and estrogen deficiency as a risk factor in dementing illness: hypothesis on the biological basis. Maturitas, 1999, 31, 95-101.
58. Spiegelman B.M. i wsp.: Through thick and thin: wasting, obesity, and TNF alpha. Cell, 1993, 73, 625-7.
59. Straub R.H. i wsp.: Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J. Clin. Endocrinol. Metab., 2000, 85, 1340-4.
60. Suda T. i wsp.: Pathogenesis of bone loss due to estrogen deficiency. Osteoporos Int. 1997, 7 Suppl 3, S43-6.
61. Tabibzadeh S. i wsp.: Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window. Hum. Reprod., 1995, 10, 2793-9.
62. Taga T. i wsp.: Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol., 1997, 15, 797-819.
63. Tang M.X. i wsp.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet, 1996, 348, 429-32.
64. Tartaglia L.A. i wsp.: Two TNF receptors. Immunol. Today, 1992, 13, 151-3.
65. Ulich T.R. i wsp.: The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation. Am. J. Pathol., 1991, 138, 521-4.
66. Wakatsuki A. i wsp.: Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation, 2002, 105, 1436-9.
67. Warenik-Szymankiewicz A.: Dlaczego warto stosować hormonalna̧ terapiȩ zastȩpcza̧? Postȩpy Nauk Med., 2000, 13, 38-45.
68. Wenger N.K. i wsp.: Cardiovascular health and disease in women. N. Engel. J. Med. 1993, 329, 247-56.
69. Wilder R.L.: Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. J. Rheumatol. Suppl. 1996, 44, 10-12.
70. Williams N. i wsp.: The role of interleukin 6 in megakaryocyte formation, megakaryocyte development and platelet production. Ciba Found. Symp., 1992, 167, 160-70.
71. Yamashita J.I. i wsp.: Medroxyprogesterone acetate and cancer cachexia: interleukin-6 involvement. Breast Cancer, 2000, 7, 130-5.